SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999; 49: 3364.
  • 2
    Moreno V, Bosch FX, Munoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 2002; 359: 10851092.
  • 3
    Castellsague X, Munoz N. Chapter 3: cofactors in human papillomavirus carcinogenesis—role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003; 31: 2028.
  • 4
    Smith JS, Green J, Berrington DG, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet. 2003; 361: 11591167.
  • 5
    Munoz N, Franceschi S, Bosetti C, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet. 2002; 359: 10931101.
  • 6
    Deacon JM, Evans CD, Yule R, et al. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer. 2000; 83: 15651572.
  • 7
    Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst. 2002; 94: 14061414.
  • 8
    Plummer M, Herrero R, Franceschi S, et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control. 2003; 14: 805814.
  • 9
    Wang SS, Hildesheim A. Chapter 5: viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr. 2003; 31: 3540.
  • 10
    Smith JS, Munoz N, Herrero R, et al. Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis. 2002; 185: 324331.
  • 11
    Smith JS, Munoz N, Franceschi S, Eluf-Neto J, Herrero R, Peeling RW. Chlamydia trachomatis and cervical squamous cell carcinoma. JAMA. 2001; 285: 17041706.
  • 12
    Smith JS, Herrero R, Bosetti C, et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst. 2002; 94: 16041613.
  • 13
    Smith JS, Bosetti C, Munoz N, et al. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer. 2004; 111: 431439.
  • 14
    Parikh S, Brennan P, Boffetta P. Meta-analysis of social inequality and the risk of cervical cancer. Int J Cancer. 2003; 105: 687691.
  • 15
    Schiffman M, Hildesheim A. Cervical cancer. In: SchottenfeldD, FraumeniJF, Jr., editors. Cancer epidemiology and prevention, 3rd ed. New York: Oxford University Press, In Press.
  • 16
    Jones CP. Invited commentary: “race,” racism, and the practice of epidemiology. Am J Epidemiol. 2001; 154: 299304.
  • 17
    Devesa SS, Diamond EL. Association of breast cancer and cervical cancer incidence with income and education among whites and blacks. J Natl Cancer Inst. 1980; 65: 515528.
  • 18
    Wang SS, Sherman ME, Hildesheim A, Lacey JV Jr., Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000. Cancer. 2004; 100: 10351044.
  • 19
    O'Brien K, Cokkinides V, Jemal A, et al. Cancer statistics for Hispanics, 2003. CA Cancer J Clin. 2003; 53: 208226.
  • 20
    Taylor VM, Jackson JC, Schwartz SM, Tu SP, Thompson B. Cervical cancer among Asian American women: a neglected health problem? Asian Am Pac Isl J Health. 1996; 4: 327342.
  • 21
    Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002; 287: 21062113.
  • 22
    Brawley OW, Freeman HP. Race and outcomes: is this the end of the beginning for minority health research? J Natl Cancer Inst. 1999; 91: 19081909.
  • 23
    Schwartz KL, Crossley-May H, Vigneau FD, Brown K, Banerjee M. Race, socioeconomic status and stage at diagnosis for five common malignancies. Cancer Causes Control. 2003; 14: 761766.
  • 24
    The Institute of Medicine. Unequal treatment; confronting racial and ethnic disparities in health care. Washington, DC: The National Academic Press, 2003.
  • 25
    Drain PK, Holmes KK, Hughes JP, Koutsky LA. Determinants of cervical cancer rates in developing countries. Int J Cancer. 2002; 100: 199205.
  • 26
    Schiffman M, Adrianza ME. ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants. Acta Cytol. 2000; 44: 726742.
  • 27
    Guido R, Schiffman M, Solomon D, Burke L. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol. 2003; 188: 14011495.
  • 28
    Cox JT, Schiffman M, Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia Grade 2 or 3 among women with cervical intraepithelial neoplasia Grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol. 2003; 188: 14061412.
  • 29
    ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol. 2003; 188: 13931400.
  • 30
    ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003; 188: 13831392.
  • 31
    Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA. 2000; 283: 8793.
  • 32
    Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000; 38: 357361.
  • 33
    Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995; 87: 796802.
  • 34
    Castle PE, Schiffman M, Burk RD, et al. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev. 2002; 11: 13941139.
  • 35
    Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001; 285: 15001505.
  • 36
    Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003; 95: 4652.
  • 37
    Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr. 2003; 31: 1419.
  • 38
    Bauer HM, Hildesheim A, Schiffman MH, et al. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sex Transm Dis. 1993; 20: 274278.
  • 39
    Hildesheim A, Gravitt P, Schiffman MH, et al. Determinants of genital human papillomavirus infection in low-income women in Washington, DC. Sex Transm Dis. 1993; 20: 279285.
  • 40
    Wheeler CM, Parmenter CA, Hunt WC, et al. Determinants of genital human papillomavirus infection among cytologically normal women attending the University of New Mexico student health center. Sex Transm Dis. 1993; 20: 286289.
  • 41
    Bach PB, Pham HH, Schrag D, Tate RC, Hargraves JL. Primary care physicians who treat blacks and whites. N Engl J Med. 2004; 351: 575584.